Telbivudine for the treatment of chronic hepatitis B infection.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 3, Issue , 2009, Pages 23-30

  Hartwell, D ^a   Jones, J ^b   Harris, P ^b   Cooper, K ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; NUCLEOSIDE; PYRIMIDINONE DERIVATIVE; TELBIVUDINE; THYMIDINE;

ADULT; COST BENEFIT ANALYSIS; ECONOMICS; HEPATITIS B; HUMAN; REVIEW;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES; THYMIDINE;

MLCS; MLOWN;

EID: 84886943105     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl3/04     Document Type: Review

References (9)